Abstract:In locally advanced esophageal cancer, the controversy over the two traditional treatment modalities, neoadjuvant radiotherapy and neoadjuvant chemotherapy, has been unending and also challenged by the addition of neoadjuvant immunotherapy. Neoadjuvant immunotherapy has led to an increasing diversity of neoadjuvant combination treatment modalities, among which neoadjuvant immunochemotherapy has emerged, with current clinical studies initially demonstrating its efficacy and safety. We report a case of a patient with locally advanced esophageal cancer who underwent two cycles of neoadjuvant immunochemotherapy and successful surgery and achieved a pathological complete response (pCR). A 73-year-old elderly female patient presented with progressive dysphagia for more than 1 month with an Eastern Cooperative Oncology Group (ECOG) score of 1. After completing gastroscopy + pathological biopsy, chest enhanced CT, barium esophageal meal, PET-CT, and other related examinations, the clinical diagnosis was thoracic segmental esophageal poorly differentiated squamous carcinoma cT2N2M0 stage III. After a multidisciplinary discussion of the comprehensive treatment plan, two cycles of neoadjuvant therapy were given on February 16, 2023, and March 9, 2023, and the treatment plan was as follows: cisplatin 30 mg d1–3 + albumin paclitaxel 200 mg d1 and 100 mg d8 + sintilimab 200 mg d4, q3w. After the neoadjuvant therapy, the patient underwent an imaging examination. The chest enhanced CT suggested that the lesion range was significantly reduced compared with the previous scan, and mediastinal lymph nodes were partially reduced. Then, thoracoscopic radical esophageal cancer surgery was performed on April 23, 2023. pCR was achieved by pathological evaluation, and the postoperative diagnosis was thoracic segmental esophageal hypofractionated squamous carcinoma ypT0N0M0. Two cycles of adjuvant immunochemotherapy were performed after surgery on May 30, 2023, and June 21, 2023, and the regimen was as follows: cisplatin 30 mg d1–3 + albumin paclitaxel 200 mg d1 and 100 mg d8 + sindilizumab 200 mg d4, q3w. As of the latest review on March 20, 2024, the patient was not seen to have any significant postoperative complications and remains in a state of complete response (CR). Neoadjuvant immunochemotherapy has positive significance for the treatment of patients with locally advanced esophageal cancer. Whether neoadjuvant immunochemotherapy can replace neoadjuvant synchronous radiotherapy is a future direction of research, which needs to be further verified by more reliable clinical trials.

History and current situation of neoadjuvant treatment for locally advanced esophageal cancer

Neoadjuvant therapy for esophageal carcinoma

Research status and progress on neoadjuvant therapy for esophageal cancer

Current neoadjuvant therapy for operable locally advanced esophageal cancer

Recent Progress in the Neoadjuvant Treatment Strategy for Locally Advanced Esophageal Cancer

[The Role of Neoadjuvant Therapy in Multimodality Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: Perspective from the NEOCRTEC5010 Trial].

Neoadjuvant immunotherapy for resectable esophageal cancer: A review

A narrative review on advances in neoadjuvant immunotherapy for esophageal cancer: Molecular biomarkers and future directions

A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer

Treatment options for neoadjuvant strategies of esophageal squamous cell carcinoma (Review)

Present situation and prospect of immunotherapy for unresectable locally advanced esophageal cancer during peri-radiotherapy

Surgical intervention after neoadjuvant therapy in esophageal cancer: a narrative review

Neoadjuvant Versus Adjuvant Treatment: Which One is Better for Resectable Esophageal Squamous Cell Carcinoma?

Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study

Case report: A case study of neoadjuvant immunochemotherapy for locally advanced esophageal squamous carcinoma

Adjuvant Therapies for Esophageal Cancer

Neoadjuvant treatment of esophageal cancer: chemotherapy, chemoradiation, immunotherapy, and future trends of therapy

Neoadjuvant Treatment for Locally Invasive Esophageal Cancer

Neoadjuvant Therapy for Non-Small Cell Lung Cancer and Esophageal Cancer

Optimal Preoperative Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Surgical treatment for esophageal cancer:current status and future directions